{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-079143","form_type":"8-K","ticker":"BCYC","cik":"0001761612","company_name":"BICYCLE THERAPEUTICS PLC","filed_at":"2022-07-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.950323+00:00","generated_at":"2026-06-24T16:52:37.084082+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Bicycle Therapeutics expands Genentech immuno-oncology collaboration; receives $10M option exercise payment","bullets":["Genentech exercised second option to add a new program to the existing 2020 collaboration, triggering a $10M payment to Bicycle.","First expansion option under the same agreement was exercised in October 2021, also for $10M.","Collaboration covers discovery and preclinical development of novel Bicycle-based immunotherapies against multiple targets.","Bicycle's wholly owned oncology pipeline, including its immuno-oncology candidates, is not part of the collaboration."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-079143","json":"https://secwatch.observer/filing/0001104659-22-079143.json","markdown":"https://secwatch.observer/filing/0001104659-22-079143.md","text":"https://secwatch.observer/filing/0001104659-22-079143.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761612/000110465922079143/0001104659-22-079143-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761612/000110465922079143/tm2220703d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T16:52:37.084082+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}